DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Pantuck AJ, Zomorodian N, Belldegrun AS.
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy.
Curr Urol Rep 2007; 8: 3-4
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.